PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsCimetidine
Cimetidine
Cimetidine, Tagamet (cimetidine) is a small molecule pharmaceutical. Cimetidine was first approved as Tagamet on 1982-01-01. It is used to treat duodenal ulcer, dyspepsia, gastroesophageal reflux, heartburn, and helicobacter infections amongst others in the USA. The pharmaceutical is active against histamine H2 receptor. In addition, it is known to target multidrug and toxin extrusion protein 2, equilibrative nucleoside transporter 4, and multidrug and toxin extrusion protein 1.
Download report
Favorite
Top OTC Drugs
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
digestive system diseasesD004066
skin and connective tissue diseasesD017437
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Cimetidine, Tagamet (discontinued: Cimetidine, Tagamet)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cimetidine
Tradename
Company
Number
Date
Products
TAGAMET HBMedTech ProductsN-020238 OTC1996-08-21
1 products, RLD, RS
Show 3 discontinued
Cimetidine hydrochloride
Tradename
Company
Number
Date
Products
TAGAMETGSKN-017924 DISCN1982-01-01
1 products
TAGAMETGSKN-017939 DISCN1982-01-01
1 products
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERGSKN-019434 DISCN1985-10-31
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
basic care acid reducerANDA2022-01-14
cimetidineANDA2025-10-20
cimetidine 10% / lidocaine 5% / salicylic acid 40%unapproved drug other2019-04-24
cimetidine 200ANDA2025-03-10
cimetidine 5% / ibuprofen 2% / salicylic acid 17%unapproved drug other2019-05-17
cimetidine hydrochlorideANDA2025-11-04
cimetidine hydrochloride oral solutionANDA2022-10-17
equate cimetidineANDA2022-03-10
heartburn preventionANDA2025-08-26
heartburn reliefANDA2022-01-05
Show 2 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
gastroesophageal refluxEFO_0003948D005764K21
helicobacter infectionsEFO_1000961D016481—
peptic esophagitisEFO_1001095D004942—
stomach ulcer—D013276K25
duodenal ulcerEFO_0004607D004381K26
dyspepsiaEFO_0008533D004415K30
zollinger-ellison syndrome—D015043E16.4
urticariaEFO_0005531D014581L50
heartburn—D006356R12
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BA: H2-receptor antagonists
— A02BA01: Cimetidine
— A02BA51: Cimetidine, combinations
HCPCS
Code
Description
S0023
Injection, cimetidine hydrochloride, 300 mg
Clinical
Clinical Trials
157 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bacterial infectionsD001424—A491————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCimetidine
INNcimetidine
Description
Cimetidine is a member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach. It has a role as a H2-receptor antagonist, a P450 inhibitor, an anti-ulcer drug, an analgesic and an adjuvant. It is a member of guanidines, a member of imidazoles, an aliphatic sulfide and a nitrile.
Classification
Small molecule
Drug classH2-receptor antagonists (cimetidine type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN/C(=N\CCSCc1nc[nH]c1C)NC#N
Identifiers
PDB—
CAS-ID51481-61-9
RxCUI—
ChEMBL IDCHEMBL30
ChEBI ID3699
PubChem CID2756
DrugBankDB00501
UNII ID80061L1WGD (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
SLC47A2
SLC47A2
Organism
Homo sapiens
Gene name
SLC47A2
Gene synonyms
MATE2
NCBI Gene ID
146802
Protein name
multidrug and toxin extrusion protein 2
Protein synonyms
Kidney-specific H(+)/organic cation antiporter, solute carrier family 47 (multidrug and toxin extrusion), member 2, Solute carrier family 47 member 2
Uniprot ID
Q86VL8
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Cimetidine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 15,057 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
5,313 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use